Search Results 1761-1770 of 17031 for monoclonal antibody

1. A First-in-Human Study Of MEN2312 In Adults With Advanced Breast Cancer - Mayo Clinic

   * Up to 6 prior lines of systemic therapy (including up to 2 prior lines consisting of chemotherapy, cytotoxic antibody drug conjugate, or a combination of ...

2. A Study to Evaluate HH2853 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphomas or Advanced Solid Tumors - Mayo Clinic

   Any cancer-directed therapy (chemotherapy, antibody therapy, radiotherapy, hormonal ... 200 IU/mL; HCV antibody test results are positive, and HCV (hepatitis C ...

3. Clinical trials - Oncology (Medical)

   ... antibodies and the factors that may determine disease progression and treatment response. Pagination Clinical studies. PrevPrevious Page · Go to page 1919 · Go ...

4. A Study of the Safety and Effectiveness of Atezolizumab Combined with Etoposide, and Carboplatin for Patients with Untreated Extensive-Stage Small Cell Lung Cancer - Mayo Clinic

   Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, anti-PD1, and anti-PD-L1 therapeutic antibody ...

5. Diphtheria, tetanus, acellular pertussis, polio vaccine (intramuscular route) - Mayo Clinic

   The vaccine works by causing the body to produce its own protection (antibodies) against these diseases. This vaccine is given only to children 4 to 6 years ...

6. Clinical trials - Oncology (Medical)

   UP-NEXT is a double-blind, randomized, placebo controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an ...

7. Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab - Mayo Clinic

   ... antibodies). New onset or signs and symptoms of any form of ... Prior exposure to any anti-IgE antibody therapy other than omalizumab and ligelizumab.

8. A Phase 1/2 Study to Evaluate MEDI4736 - Clinical Trials

   Prior exposure to any anti-PD-1 or anti-PD-L1 antibody; Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Prior ...

9. Pilot Clinical Trial Evaluating the Utility of Minocycline as an Agent to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Placebo-Controlled, Double Blind Trial - Mayo Clinic

   ... antibody and/or small molecule treatment is allowed, except for PARP inhibitors). Life expectancy >6 months; ECOG performance status 0 or 1. (Form is ...

10. Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

    Diagnosis of smoldering MM, Waldenström's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) ...